Sign inJoin waitlistJoin the waitlist

JE

John Ellerton

Clinical Assistant Professor · Kirk Kerkorian School of Medicine at UNLV

Credentials: · · · · · ·

History

Kirk Kerkorian School of Medicine at UNLV
Present

Hematology and Medical Oncology
1977–1980
Internal Medicine
1974–1977
Doctor of Medicine
1970–1974

Research

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B
Journal of Clinical Oncology · 2002 · 1,495 citations
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
New England Journal of Medicine · 1994 · 583 citations
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
The Lancet Oncology · 2018 · 469 citations

Ken Zafren
5 papers
CS
Charles Schiffer
3 papers
Giles Peek
3 papers
MG
Mark Green
3 papers
Andrea Apolo
2 papers
AM
Antonius Miller
2 papers
Bayard Powell
2 papers
Carlos DeCastro
2 papers
DD
David Duggan
2 papers
DW
Ding Wang
2 papers
HO
Howard Ozer
2 papers
IH
Isaac Henderson
2 papers

Grants

NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Required)
National Cancer Institute · UG1
Contact PI · $14M · Southern Nevada Cancer Research Fdn
2014–2026
Nevada Cancer Research Foundation-Community Clinical Oncology Program
National Cancer Institute · U10
Contact PI · $12.7M · Southern Nevada Cancer Research Fdn
1983–2015

Clinical trials

Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer
Principal investigator · Completed · Phase 2
Daehwa Pharmaceutical Co., Ltd.
2018–2022
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Site PI · Recruiting
Wake Forest University Health Sciences
2025–2028
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
Site PI · Recruiting · Phase 2
Alliance for Clinical Trials in Oncology
2024–2026
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2024–2028